Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (January 2002). "A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers". Human Psychopharmacology. 17 (1): 1–13. doi:10.1002/hup.320. PMID12404702. S2CID23877366.
Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (October 2008). "Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine". Schizophrenia Research. 105 (1–3): 224–235. doi:10.1016/j.schres.2008.07.005. PMID18710798. S2CID11315672.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID16774655. S2CID6267180.
Isbister GK, Balit CR, Macleod D, Duffull SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". Journal of Clinical Psychopharmacology. 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID20531221. S2CID205710487.
Joy JP, Coulter CV, Duffull SB, Isbister GK (August 2011). "Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses". Clinical Pharmacology and Therapeutics. 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID21716272. S2CID26412012.
Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (April 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". European Journal of Pharmacology. 256 (2): 211–214. doi:10.1016/0014-2999(94)90248-8. PMID7914168.
Blomme A, Conraux L, Poirier P, Olivier A, Koenig JJ, Sevrin M, Durant F, George P (2000). "Amisulpride, Sultopride and Sulpiride: Comparison of Conformational and Physico-Chemical Properties". Molecular Modeling and Prediction of Bioactivity. Springer US. pp. 404–405. doi:10.1007/978-1-4615-4141-7_97. ISBN978-1-4613-6857-1.
Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lempérière T, et al. (2001). "Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia". Neuropsychobiology. 44 (1): 41–46. doi:10.1159/000054913. PMID11408792. S2CID21103201.
"Active substance: amisulpride"(PDF). 28 September 2017. EMA/658194/2017; Procedure no.: PSUSA/00000167/201701. Archived from the original(PDF) on 15 June 2018. Retrieved 26 February 2020.
Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (January 2002). "A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers". Human Psychopharmacology. 17 (1): 1–13. doi:10.1002/hup.320. PMID12404702. S2CID23877366.
Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (October 2008). "Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine". Schizophrenia Research. 105 (1–3): 224–235. doi:10.1016/j.schres.2008.07.005. PMID18710798. S2CID11315672.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID16774655. S2CID6267180.
Isbister GK, Balit CR, Macleod D, Duffull SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". Journal of Clinical Psychopharmacology. 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID20531221. S2CID205710487.
Joy JP, Coulter CV, Duffull SB, Isbister GK (August 2011). "Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses". Clinical Pharmacology and Therapeutics. 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID21716272. S2CID26412012.
Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (April 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". European Journal of Pharmacology. 256 (2): 211–214. doi:10.1016/0014-2999(94)90248-8. PMID7914168.
Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. (January 1997). "Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity". The Journal of Pharmacology and Experimental Therapeutics. 280 (1): 83–97. PMID8996185.
Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lempérière T, et al. (2001). "Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia". Neuropsychobiology. 44 (1): 41–46. doi:10.1159/000054913. PMID11408792. S2CID21103201.
Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (January 2002). "A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers". Human Psychopharmacology. 17 (1): 1–13. doi:10.1002/hup.320. PMID12404702. S2CID23877366.
Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (October 2008). "Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine". Schizophrenia Research. 105 (1–3): 224–235. doi:10.1016/j.schres.2008.07.005. PMID18710798. S2CID11315672.
Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID16774655. S2CID6267180.
Isbister GK, Balit CR, Macleod D, Duffull SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". Journal of Clinical Psychopharmacology. 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID20531221. S2CID205710487.
Joy JP, Coulter CV, Duffull SB, Isbister GK (August 2011). "Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses". Clinical Pharmacology and Therapeutics. 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID21716272. S2CID26412012.
Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lempérière T, et al. (2001). "Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia". Neuropsychobiology. 44 (1): 41–46. doi:10.1159/000054913. PMID11408792. S2CID21103201.
Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
"Active substance: amisulpride"(PDF). 28 September 2017. EMA/658194/2017; Procedure no.: PSUSA/00000167/201701. Archived from the original(PDF) on 15 June 2018. Retrieved 26 February 2020.